LIDDS: Another (potential) weapon against cancer

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

Not likely

Very likely

Not likely

Very likely

Message received

Thanks again for rating us!

LIDDS: Another (potential) weapon against cancer

Jakob Svensson

2019-04-23

05:30

Earlier in April LIDDS announced a new project, a Toll-Like Receptor 9 (TLR9) formulated with the NanoZolid platform. Positive preclinical data have been generated so far and LIDDS aims to start Phase I in 2020. We have included the new project in our valuation which raising our valuation range slightly.

Disclosures and disclaimers

Premium Plan required to unlock